International Cancer Conference Journal最新文献

Advancing immunotherapy in oncology. 肿瘤免疫治疗的进展。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-06-24 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00784-9

Noriomi Matsumura

引用次数: 0

Definitive chemoradiotherapy for pulmonary epithelial-myoepithelial carcinoma. 肺上皮-肌上皮癌的决定性放化疗。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-06-08 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00779-6

Keijiro Yamauchi, Masashi Yokoyama, Kayo Ueda, Riiko Komuta, Hidetaka Tanabe, So Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hideo Mori, Hidekazu Suzuki

引用次数: 0

A rare case of primary prostate melanoma with extensive secondaries: case report. 罕见的原发性前列腺黑色素瘤伴广泛继发病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-06-06 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00778-7

Kumanan Jayaraman, Rejeesh Selvaganesan, Binitta Sherin

引用次数: 0

A rare case of ALK-positive histiocytosis with neurological involvement in a 70-year-old woman successfully managed with partial resection and alectinib. 一例罕见的alk阳性组织细胞增多症伴神经系统病变，患者为70岁，经部分切除和alectinib治疗成功。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-06-03 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00776-9

Eiichiro So, Norihito Ishida, Akihiko Chida, Sara Horie, Shotaro Kishimoto, Kai Tsugaru, Hideyuki Hayashi, Yuya Koda, Masahiro Ozaki, Hajime Okita, Takanori Kanai, Kenro Hirata

引用次数: 0

Extended survival in a patient with leptomeningeal disease related to EGFR exon 19 deletion metastatic non-small cell lung cancer: a case report. 与EGFR外显子19缺失相关的轻脑膜疾病转移性非小细胞肺癌患者的延长生存期：1例报告

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-31 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00777-8

Ehab Harahsheh, Vinicius Ernani, Skyler J Taylor, Kliment Donev, Maciej M Mrugala

引用次数: 0

Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care. 低剂量口服环磷酰胺联合或不联合贝伐单抗治疗复发性卵巢癌和宫颈癌患者在最佳支持治疗前。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-30 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00775-w

Yusuke Kawaguchi, Ryusuke Murakami, Akihiro Yanai, Haruka Mieda, Azusa Sakurai, Saki Sawayama, Mie Sakai, Hirofumi Nonogaki, Yumi Takao

{"title":"Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care.","authors":"Yusuke Kawaguchi, Ryusuke Murakami, Akihiro Yanai, Haruka Mieda, Azusa Sakurai, Saki Sawayama, Mie Sakai, Hirofumi Nonogaki, Yumi Takao","doi":"10.1007/s13691-025-00775-w","DOIUrl":"https://doi.org/10.1007/s13691-025-00775-w","url":null,"abstract":"This study evaluates the efficacy and tolerability of low-dose oral cyclophosphamide, with or without bevacizumab, in treating recurrent ovarian and cervical cancer among patients heavily pretreated with platinum-based chemotherapy. It presents case reports of individuals who received low-dose cyclophosphamide (50 mg/day) and bevacizumab (15 mg/kg per cycle for three to four weeks) in a metronomic treatment approach. Focusing on three significant cases from a cohort of eleven treated with these regimens, the case report demonstrates partial responses, delayed disease progression, and minimal adverse effects. These findings highlight the regimen's potential to maintain quality of life and performance status. The study underscores the therapeutic benefits and mild toxicity profile of low-dose cyclophosphamide with or without bevacizumab, suggesting its potential as a viable treatment option for patients with extensive treatment history. This regimen is particularly promising in settings prioritizing quality of life.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"319-326"},"PeriodicalIF":0.5,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report. 三氟定/替吡拉西联合贝伐单抗治疗转移性尿管癌1例

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-27 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00768-9

Takafumi Kitazono, Taichi Isobe, Satoshi Nishiyori, Wataru Kusano, Kenro Tanoue, Tomoyasu Yoshihiro, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Kenji Tsuchihashi, Koichi Akashi, Eishi Baba

{"title":"Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report.","authors":"Takafumi Kitazono, Taichi Isobe, Satoshi Nishiyori, Wataru Kusano, Kenro Tanoue, Tomoyasu Yoshihiro, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Kenji Tsuchihashi, Koichi Akashi, Eishi Baba","doi":"10.1007/s13691-025-00768-9","DOIUrl":"https://doi.org/10.1007/s13691-025-00768-9","url":null,"abstract":"A 53-year-old man with a tumorous lesion at the bladder apex was diagnosed with an unresectable urachal carcinoma. After 10 cycles of combined therapy with 5-fluorouracil, leucovorin, and oxaliplatin, a combination of trifluridine/tipiracil and bevacizumab was initiated as second-line chemotherapy. Despite requiring a switch to bevacizumab monotherapy after the sixth cycle due to hematological toxicity, this regimen effectively controlled the disease for 16 cycles. It resulted in a progression-free survival of 17 months. To the best of our knowledge, this is the first report documenting the use of trifluridine/tipiracil and bevacizumab combination therapy for urachal carcinoma. While the observed disease control was notable in this patient, further accumulation of clinical experience and careful evaluation are warranted before generalizing the efficacy of this regimen in this rare malignancy.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"280-288"},"PeriodicalIF":0.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral osteonecrosis of the external auditory canal caused by bone-modifying agents for cancer bone metastases. 肿瘤骨转移的骨修饰剂引起的双侧外耳道骨坏死。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-27 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00772-z

Sayaka Yamaguchi, Tomoaki Mori, Naofumi Asano, Michiro Susa, Naoki Oishi, Hiroyuki Ozawa, Robert Nakayama

{"title":"Bilateral osteonecrosis of the external auditory canal caused by bone-modifying agents for cancer bone metastases.","authors":"Sayaka Yamaguchi, Tomoaki Mori, Naofumi Asano, Michiro Susa, Naoki Oishi, Hiroyuki Ozawa, Robert Nakayama","doi":"10.1007/s13691-025-00772-z","DOIUrl":"https://doi.org/10.1007/s13691-025-00772-z","url":null,"abstract":"A 51-year-old woman with a 54-month history of treatment with bone-modifying agents for thyroid cancer bone metastases, namely zoledronic acid for three months and denosumab for 51 months, presented with jaw pain, trismus, and ear discharge. Physical examination, bacterial culture, and radiological findings led to a diagnosis of osteonecrosis of the external auditory canal. Since the discontinuation of denosumab did not improve the diagnosed condition, she underwent surgical reconstruction. Bone-modifying agents such as zoledronic acid and denosumab, which are commonly used to prevent skeletal-related events in patients with bone metastases from various cancers, have been used for several years, especially for patients with slow-growing cancers. Osteonecrosis of the external auditory canal is an infrequent but serious adverse event caused by prolonged use of bone-modifying agents. Therefore, clinicians should be fully aware of its potential risks in the long-term management of bone metastasis.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"311-318"},"PeriodicalIF":0.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete response to pembrolizumab in mismatch repair-deficient urothelial carcinoma with local recurrence and recurrent upper tract urothelial carcinoma: a case report. 派姆单抗对错配修复缺陷尿路上皮癌局部复发和复发上尿路上皮癌的完全缓解：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-24 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00774-x

Koichi Shiraishi, Masaki Shiota, Genshiro Fukuchi, Tokiyoshi Tanegashima, Shigehiro Tsukahara, Jun Mutaguchi, Satoshi Kobayashi, Takashi Matsumoto, Yoshinao Oda, Masatoshi Eto

{"title":"Complete response to pembrolizumab in mismatch repair-deficient urothelial carcinoma with local recurrence and recurrent upper tract urothelial carcinoma: a case report.","authors":"Koichi Shiraishi, Masaki Shiota, Genshiro Fukuchi, Tokiyoshi Tanegashima, Shigehiro Tsukahara, Jun Mutaguchi, Satoshi Kobayashi, Takashi Matsumoto, Yoshinao Oda, Masatoshi Eto","doi":"10.1007/s13691-025-00774-x","DOIUrl":"https://doi.org/10.1007/s13691-025-00774-x","url":null,"abstract":"Clinical evidence supporting the use of PD-1/PD-L1 inhibitors in treating urothelial carcinoma with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) remains limited. We report a case of 77-year-old male with a history of multiple cancers. Immunohistochemical staining of bladder tumor revealed the loss of MSH2 and MSH6 expression, and MSI-H by PCR-based method and pathogenic alterations in MSH2 and MSH6 genes by next generation sequencing were confirmed, suggesting Lynch syndrome. He received pembrolizumab for local recurrence after total pelvic exenteration and recurrent upper tract urothelial carcinoma, and achieved complete remission. This case supports the potential of PD-1/PD-L1 inhibitors as a promising treatment option for MSI-H or dMMR urothelial carcinoma, similar to other solid tumors with MSI-H or dMMR.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"198-203"},"PeriodicalIF":0.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary carcinosarcoma of the uterine cervix with somatic mutations of the ATM and NF2 genes: a case report. 宫颈原发性癌肉瘤伴ATM和NF2基因体细胞突变1例

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-24 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00770-1

Taichi Irie, Yasushi Iida, Yoshinobu Hamada, Jun Matsushima, Makoto Iizuka, Satoshi Takakura

{"title":"Primary carcinosarcoma of the uterine cervix with somatic mutations of the ATM and NF2 genes: a case report.","authors":"Taichi Irie, Yasushi Iida, Yoshinobu Hamada, Jun Matsushima, Makoto Iizuka, Satoshi Takakura","doi":"10.1007/s13691-025-00770-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00770-1","url":null,"abstract":"Primary carcinosarcomas are a rare type of cervical tumors. A 75-year-old female patient diagnosed with stage IB2 cervical carcinosarcoma (CCS) was treated with radical surgery followed by adjuvant chemoradiotherapy. She survived without recurrence for 3 years after the surgery. Double somatic mutations of the ATM (c.802C > T [p.Glu268*], variant allele frequency [VAF] of 48.5%, and c.7181C > T [p.Ser2394Leu], VAF of 45.1%) and NF2 (c.1021C > T [p.Arg341*], VAF of 2.4%) genes were detected in the CCS via next-generation sequencing analyses. Retrospective studies using large databases should be performed to establish a consensus regarding the use of combination therapies in elderly patients with primary CCS. To the best of our knowledge, this report first revealed the presence of ATM mutations in a patient with primary CCS. Previous studies and the current data showed therapeutic possibilities for the subsets of gynecologic carcinosarcoma and provided information on the molecular mechanism of its development.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"302-310"},"PeriodicalIF":0.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0